Scopio Labs

Company Overview

Snapshot

Founded in October 2014 by Itai Hayut and Erez Na'aman, Scopio Labs has grown to 51–200 employees. The company has raised over $126.76 million across 8 funding rounds from 13 investors. In July 2024, Scopio Labs secured a Series D funding round led by.

Business overview

Scopio Labs develops a proprietary diagnostics platform centered on computational microscopy to provide accessible and high-quality microscopic analysis. Their technology merges hardware and software to automate and enhance traditional manual examination processes, serving clinical laboratories and healthcare providers. The company's solutions, including the Full-Field Peripheral Blood Smear Application on the X100, leverage AI-powered decision support systems and remote connectivity to improve diagnostic precision and efficiency in hematology.

Strategic signal

In April 2026, Scopio Labs secured EU IVDR certification for its Full-Field Digital Bone Marrow Application, a significant regulatory achievement that validates the company's advanced digital morphology solutions for the European market. This certification, following previous FDA clearances, underscores Scopio Labs' commitment to meeting global standards and expanding the reach of its AI-driven diagnostic platforms, signaling strong market penetration potential and regulatory confidence to investors.

Company Intelligence Q&A

What was a key regulatory achievement for Scopio Labs in April 2026?

In April 2026, Scopio Labs secured EU IVDR certification for its Full-Field Digital Bone Marrow Application, enabling its use in the European market.

What strategic partnership did Scopio Labs expand in January 2025?

In January 2025, Scopio Labs expanded its strategic alliance with Siemens Healthineers to include the global distribution of its Full-Field Bone Marrow Aspirate (FF-BMA) Application.

What was the outcome of Scopio Labs' Series D funding round in July 2024?

In July 2024, Scopio Labs secured a Series D funding round led by.

What significant regulatory clearance did Scopio Labs receive in April 2024?

In April 2024, Scopio Labs received De Novo clearance from the US FDA for its Full-Field Bone Marrow Aspirate (FF-BMA) Application, accelerating the transition to AI-powered digital hematopathology.

What partnership did Scopio Labs announce in February 2023 to enhance its market strategy?

In February 2023, Scopio Labs announced a global distribution agreement with Beckman Coulter, a leader in clinical diagnostics, to accelerate market penetration for its digital cell morphology solutions.